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Abstract
Liver disease epidemiology in sub-Saharan Africa has shifted as a result of HIV and the in-
creased use of antiretroviral therapy leading to a need for updated data on common causes
of liver disease. We retrospectively reviewed records from all hospitalized patients who had
liver biopsy at a single hospital in South Africa from 2001 to 2009 and compared diagnosis
by HIV status. During the period of study 262 patients had liver biopsy, 108 (41%) were
HIV-infected, 25 (10%) were HIV-sero-negative, and 129 (49%) had unknown or unrecord-
ed HIV status. Overall 81% of biopsies provided additional diagnostic data. Malignancy was
the most common finding reported on 56 (21%) biopsies followed by granuloma or TB, he-
patic steatosis, and fibrosis or cirrhosis. HIV-infected patients were more likely to have gran-
ulomas and steatosis. Half of patients with granulomas were already on TB treatment,
suggesting paradoxical reactions or drug induced liver injury may have been important
causes of liver inflammation among these patients. We note that TB, paradoxical reactions
during TB treatment, possible drug induced liver injury, and hepatic steatosis are important
causes of liver pathology among HIV-infected hospitalized patients with unclear etiology of
liver disease after initial assessment. Among HIV sero-negative patients, malignancy was
the major cause of liver disease. Our findings re-enforce the importance of TB as a diagno-
sis among HIV-infected individuals.
Introduction
Biochemical abnormalities suggesting liver disease are common among patients [1], particular-
ly hospitalized patients [2]. Liver abnormalities in transaminases, bilirubin, and alkaline phos-
phatase can be due to primary liver disease or may be a manifestation of systemic illness;
determining the cause may guide therapy [2,3]. In settings with constrained clinical and
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diagnostic resources identification of etiology can be challenging. In many resource-limited set-
tings a valuable tool for assessing liver disease, liver biopsy, is challenging or impossible to ob-
tain. In settings where extensive investigations are not possible, understanding the local
epidemiology of liver disease is essential for developing a differential diagnosis to guide
decision making.
The emergence of HIV in Africa has led to an increase in opportunistic infections, particu-
larly tuberculosis, and HIV-related malignancies, all of which may involve the liver [4–6]. In
addition, medications used to treat these conditions, including antiretroviral therapy (ART),
preventive therapies prescribed to people living with HIV (cotrimoxazole and isoniazid), and
TB treatment have potentially hepatotoxic effects. Chronic viral hepatitis, especially hepatitis B
virus, are also important causes of morbidity in Africa and are likely to have accelerated pro-
gression among HIV-co-infected individuals [7]. Insight into current causes of liver disease is
important for clinicians working in sub-Saharan Africa. To characterize current epidemiology
of liver disease we retrospectively reviewed clinical liver biopsy findings in HIV-infected, sero-
negative, and unknown status individuals with liver disease of unclear etiology after clinical,
laboratory, and radiographic assessments at a single center in South Africa.
Methods
Population
This research was conducted according to the principles expressed in the Declaration of Hel-
sinki. This study was retrospective without interaction with patients, thus written informed
consent was not obtained. All data abstraction forms were devoid of personal identifiers (all
data were de-identified prior to data capture and data analysis). Approvals for the study were
received from the Johns Hopkins University and the University of the Witwatersrand
ethics committees.
Patients included in this study were adult patients (18 years and older) admitted to a single
regional hospital in the North West Province of South Africa, between 2001 and 2009 who un-
derwent a liver biopsy during their stay. This hospital draws patients from a catchment area
with both a high prevalence of HIV (20% adult prevalence) and TB [8]. Patients who under-
went liver biopsy were without a clear diagnosis after initial clinical evaluation, laboratory test-
ing, and imaging. Individuals with symptoms and laboratory tests consistent with acute viral
hepatitis, hepatocellular carcinoma, liver abscess, metastatic cancer, or who had rapid resolu-
tion of the hepatitis (within 2–5 days of admission) were generally not considered candidates
for biopsy. A single internist evaluated all patients for biopsy and performed all liver biopsies
during the study period. Biopsy results were obtained from the National Health Laboratory
Service Anatomical Pathology Department. Hospital charts from the period of admission dur-
ing which the biopsy was done were abstracted onto a standardized tool by trained staff.
Analysis
We categorized histopathological results, using the dominant reported pattern, into the follow-
ing five general groups: granuloma with or without acid fast bacilli, hepatic steatosis, cholan-
giopathy, fibrosis or cirrhosis, and malignancy. Granuloma and acid fast bacilli were combined
in one group as this finding was nearly always either reported to be consistent with TB, or gran-
ulomas were reported to contain acid fast bacilli. We described the demographic data and re-
sults by HIV status, classified as known HIV-sero-negative, HIV-infected, and unknown HIV
status. Included with cholangiopathic processes are processes of bile duct degeneration and
vanishing bile duct syndromes; these syndromes fit the broader pathological description of
ductopenic processes. Therefore we have used the term ductopenic to describe this subset of
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cholangiopathy. Chi-square, Wilcoxon rank sum, and Kruskal-Wallis tests were used to assess
for differences with an alpha of<0.05. For patients with HIV, we have presented the range of
CD4 count and biochemical test results for each diagnostic category along with Kruskal-Wallis
testing for difference. We further provided an overall description of additional histopathologic
findings, especially findings considered secondary during the histopathological review.
Results
Between January 2001 and December 2009, 262 patients with liver disease of unclear etiology
had a liver biopsy. Of these, 108 (41%) were HIV-infected, 25 (10%) were HIV-sero-negative,
and 129 (49%) had unknown or unrecorded HIV status during the hospitalization (Table 1).
HIV-infected patients were younger, with a median age of 34 years [interquartile range (IQR):
31, 45] compared to 55 years (IQR: 40, 64; Wilcoxon rank sum p<0.001) for those sero-nega-
tive for HIV. Overall, 95% were black, 1% were Asian, and 4% were white. HIV-infected pa-
tients were receiving ART (44%), cotrimoxazole (34%), and/or TB treatment (44%); 19% were
receiving all three. Among HIV-sero-negative and HIV unknown status patients, 3 (13%) and
Table 1. Patient characteristics.
HIV-infected HIV-sero-negative unknown HIV status
N 108 25 129
Sex
Male 49 (45) 15 (60) 62 (48)
Female 59 (55) 10 (40) 67 (52)
Age 34 (31, 45) 55 (40, 64) 47 (34, 56)
Reported alcohol use (35 with recorded history)
None 15 (65) 1 (20) 4 (57)
Moderate 1 (4) 0 2 (28)
Heavy 7 (30 4 (80) 1 (14)
HBsAg results
Negative 49 (45) 10 (40) 13 (10)
Positive 8 (7) 1 (4) 1 (1)
Not tested 51 (47) 14 (56) 115 (89)
HCV antibody test result
Negative 56 (52) 8 (32) 12 (9)
Positive 2 (2) 1 (4) 1 (1)
Not tested 50 (46) 16 (64) 116 (90)
Receiving TB treatment on admission 48 (44) 3 (13) 2 (2)
Receiving ART on admission 48 (44) NA NA
Receiving cotrimoxazole on admission (34) NA NA
Histopathologic diagnoses
Granuloma or TB 28 (26) 2 (8) 11 (8)
Cholangiopathy 12 (11) 3 (12) 6 (4)
Steatosis 23 (21) 3 (12) 10 (8)
Malignancy 13 (12) 6 (24) 37 (29)
Fibrosis 9 (8) 5 (20) 22 (17)
Non-diagnostic or inadequate 16 (15) 9 (36) 32 (25)
HBsAg: hepatitis B surface antigen
HCV: hepatitis C virus
doi:10.1371/journal.pone.0117813.t001
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2 (2%), respectively, were receiving TB treatment at the time of biopsy. An alcohol history was
recorded in the medical records of 35 patients; 20 reported no alcohol use, 3 reported moder-
ate, and 12 reported heavy alcohol consumption. Prevalence of hepatic seromarkers in those
tested was hepatitis A IgM positive among 0 of 81; hepatitis B surface antigen positive among 8
of 81 (10%); hepatitis C antibody positive among 4 of 80 (5%; no HCV RNA results were avail-
able), and Schistosoma antibody, positive among 0 of 44.
Overall 81% of biopsies provided diagnostic data. Among HIV-infected patients, 15% were
non-diagnostic compared with 8% of HIV sero-negative patients and 25% with unknown HIV
status. Findings were as follows: granuloma (with or without identification of acid fast bacilli),
41 (16%); cholangiopathy, 21 (8%); steatosis, 36 (14%); malignancy, 56 (21%); fibrosis, 36
(14%); other, 21 (8%); a non-diagnostic pattern 45 (17%), and an inadequate specimen 6
(2.2%) (Table 1). Of the 36 with fibrosis, 12 (33%) had cirrhosis. Ten of the biopsies were con-
sistent with drug induced liver injury; 8 of these were among HIV-infected patients.
Compared to HIV seronegative patients, those infected with HIV were more likely to have
granulomas or definite TB; 28/108 (26%) patients with HIV compared to 2/25 (8%) HIV-sero-
negative patients and 11/129 (8.5%) with unknown HIV status; p = 0.001. Forty-nine percent
of patients with granulomas were receiving TB treatment at the time of hospitalization (prior
to biopsy), 19 of whom were HIV-infected, 1 was HIV-negative, and there were none with un-
known HIV status. The majority with HIV were also receiving ART [15 of 28 (53%)]; the medi-
an CD4 count for those with HIV and granulomas was 135 cells/mm3 (IQR: 69, 226).
Compared to HIV sero-negative patients, those infected with HIV were more likely to have
steatosis [30/108 (28%) versus 3/25 (12%), p = 0.001]. Female sex was also associated with stea-
tosis (34% of all women versus 17% of men, p = 0.02). Twelve of the 30 with HIV were on ART
at the time of admission, all were either receiving stavudine (5) or the ART regimen was not re-
corded (7) but was likely to have been stavudine given the guidelines in use at that time. The
median CD4 count among HIV-infected patients with steatosis was 176 cells/mm3 (IQR: 91,
253). We did not identify any other risk factors for steatosis.
HIV-infected patients were also more likely to have cholangiopathy compared to HIV sero-
negative patients [19/108 (18%) compared to 3/25 (12%), p = 0.006]. Five HIV-infected pa-
tients had the specific diagnosis of HIV-associated cholangiopathy based on histopathology
(others may also have had HIV-associated cholangiopathy as the diagnosis generally uses clini-
cal and histopathological data). In addition, among HIV infected adults, ductopenic histopa-
thology was associated with cotrimoxazole use (35% receiving cotrimoxazole versus 8% not
receiving cotrimoxazole, p = 0.001) and TB treatment (27% receiving TB medications versus
10% not receiving TB treatment, p = 0.02). Of note, 58% of patients receiving TB treatment
were also receiving cotrimoxazole. The median CD4 count among HIV-infected patients with
cholangiopathy was 105 cells/mm3 (IQR: 60, 494). There was no association with those receiv-
ing ART and cholangiopathy.
Fibrosis or cirrhosis was not associated with HIV serostatus, but was increased with female
sex (p = 0.02) and older age trended toward association (p = 0.06). The median CD4 count
among HIV-infected patients with fibrosis or cirrhosis was 365 cells/mm3 (306, 513). When ex-
cluding fibrosis and limiting analysis to cirrhosis, older age was associated with cirrhosis versus
not having cirrhosis (p = 0.004) while female sex lost association.
Malignancies were diagnosed in 21% of patients; men were more likely to have a biopsy
demonstrating malignancy than women [15/60 (25%) men compared to 6/73 (8%) women,
p = 0.008]. Most malignancies were found among individuals who were sero-negative for HIV
or had unknown HIV status. The exception was lymphoma: 8 of the 11 with lymphoma were
HIV-infected, representing 62% of all malignancies diagnosed among HIV-infected individuals
(the other 3 lymphoma cases were among the unknown HIV status group). The types of
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malignancy were as follows: metastatic adenocarcinoma, 13 (39%); hepatocellular carcinoma,
11 (20%); lymphoma, 11 (20%); and other, 12 (21%). Specific testing for viral hepatitis was not
completed on any of the patients diagnosed with hepatocellular carcinoma.
A number of additional findings were reported. For example, three patients had biopsy find-
ings consistent with chronic hepatitis B, one with chronic hepatitis C, and one with Schisto-
soma infection. Specific serology was available for only one of the patients, one with biopsy
findings consistent with chronic hepatitis B and serology positive for HBsAg. Three additional
patients had a secondary finding of iron overload, two of whom had primary diagnoses of gran-
ulomas consistent with TB and one had a primary diagnosis of cirrhosis without a
clear etiology.
Among HIV-infected patients we additionally compared biochemical test results by diag-
nostic category (Table 2). Patients with cholangiopathy had the lowest median CD4 count (al-
though p>0.05) and highest median alkaline phosphatase [median: 462 (IQR: 328, 1757)].
AST was highest among patients with granulomas and steatosis [105 U/L (IQR: 72, 260) and
112 U/L (101, 122), respectively] but those differences were not statistically significant. Median
values of other biochemical markers varied less by pathology.
Discussion
There are limited data on histopathologic findings among hospitalized individuals with liver
disease from a high HIV prevalence African setting. We believe that our study adds further in-
sight regarding common patterns of clinically undiagnosed liver disease among patients in this
setting. Our findings highlight the role tuberculosis and drug induced liver injury in contribut-
ing to liver derangements. Cotrimoxazole was most clearly associated with drug induced liver
injury as it was associated with a ductopenic process, a previously observed association [9,10].
We also note a high proportion of HIV-infected individuals had hepatic steatosis.
Increased granulomatous liver disease among HIV-infected individuals is consistent with
the known association between TB and HIV. However, the relative proportion of liver disease
of initial unclear etiology caused by either TB disease (previously undiagnosed) or anti-TB
therapy or paradoxical reaction to TB has not been previously described [11,12]. A drug injury
may warrant a modification in the TB treatment regimen, while a paradoxical reaction should
not prompt a change in regimen [13]. Among patients already on stable ART and TB treat-
ment, we suspect that drug injury contributed to liver inflammation and was interpreted as
such by the pathologist among 10 patients. Notably, we cannot exclude the possibility of a par-
adoxical reaction misinterpreted as a drug reaction. Drug induced liver injury is commonly re-
ported among patients with HIV, especially those receiving ART [14–18]. These studies
Table 2. Primary histopathology and laboratory findings for HIV-infected patients.
Granulomatous disease / TB Cholangiopathy Steatosis Malignancy* Fibrosis/cirrhosis p
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
n (%) 28 (26) 11 (10) 23 (21) 11 (10) 7 (6)
CD4 count (cells/mm3) 135 (69, 226) 105 (60, 494) 176 (91, 253) 225 (89, 362) 365 (306, 513) 0.5
ALT (U/L) 57 (45, 112) 31 (20, 63) 50 (41, 76) 194 63 (43, 113) 0.5
AST (U/L) 105 (72, 260) 47 (10, 59) 112 (101, 122) 271 98 (52, 155) 0.4
Alkaline phosphatase (U/L) 382 (219, 713) 462 (328, 1757) 275 (260, 359) 1913 200 (187, 307) 0.03
Total bilirubin (μmol/L) 28 (13, 40) 11 (5, 20) 18 (12, 33) 96 24 (19,105) 0.5
*Patients with malignancy lacked most laboratory data
doi:10.1371/journal.pone.0117813.t002
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reporting drug induced liver injury among patients receiving ART are generally based on
serum laboratory markers and rarely include histopathological findings or data to exclude
other processes. Depending on the local prevalence of TB and other illnesses and the ART
agents used, it is plausible that the reported incidence of hepatotoxicity from such studies also
includes non-drug related liver disease [19].
Hepatic steatosis is a complication of some antiretroviral therapy, especially stavudine, an
agent that was widely used in South Africa during the time-frame of this study [20]. In addition
to medications, steatosis is associated with alcohol use and obesity, both of which are highly
prevalent in South Africa [21–23]. However there is no reason to believe that obesity or alcohol
use are significantly increased among the HIV-infected individuals compared to HIV-seroneg-
ative or unknown status patients in this study. Thus the steatosis we found is likely due to HIV
infection, its treatment, or both. Hepatic steatosis can progress to liver fibrosis and a decline in
liver function and is considered an important cause of chronic liver disease in high-income
countries [21]. With increasing survival among people living with HIV in low and middle in-
come settings it may also become an important cause of morbidity in such settings.
This study has the strength of data coming from a routine practice with a single physician
selecting patients for biopsy and performing the biopsies. Clear limitations include the lack of
representative sampling and missing data. HIV status was unknown for many patients because,
during part of the study period, HIV testing was predominantly available in the outpatient set-
ting. Other data were variably missing, for example most HIV-infected patients with malignan-
cy did not have results from biochemical testing and hepatitis B antigen testing was completed
for less than half of the patients the study. In addition, this study reflects only the subset of pa-
tients with liver disease of unclear etiology after an initial evaluation who then went on to have
a liver biopsy. This is an important limitation because patients with laboratory diagnosed hepa-
titis B or liver masses associated with a markedly elevated alpha-fetoprotein were generally un-
likely to get a biopsy. We highlight that chronic viral hepatitis, especially chronic hepatitis B, is
an important cause of liver disease, both chronic and acute, in much of Africa [7]. Alcoholic
hepatitis and alcohol related chronic liver disease are additional important causes of liver dis-
ease in South Africa [24]. Because of the nature of this study, we would expect both hepatitis B-
related and alcohol-related liver disease to be underrepresented among patients who had biop-
sies for the purposes of diagnosis. Finally, we included HIV-sero-negative and unknown HIV
status patients in order to provide a point of comparison. It is important to note that we had a
small sample of HIV-negative patients and that those with unknown HIV status represent a
mix of HIV-infected and sero-negative patients.
Liver disease is an important cause of morbidity in resource limited settings [25,26]. In set-
tings similar to the one studied, with a high prevalence of HIV and TB, we believe our results
may help to refine a differential diagnosis. Furthermore the findings highlight the importance
of undiagnosed TB and TB medications or paradoxical reaction as a cause of liver disease.
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